Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) EBITDA (2017 - 2025)

Historic EBITDA for Selectis Health (GBCS) over the last 14 years, with Q3 2025 value amounting to $67739.0.

  • Selectis Health's EBITDA rose 10849.24% to $67739.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$175795.0, marking a year-over-year increase of 9559.11%. This contributed to the annual value of -$2.7 million for FY2024, which is 6258.41% up from last year.
  • Per Selectis Health's latest filing, its EBITDA stood at $67739.0 for Q3 2025, which was up 10849.24% from -$87547.0 recorded in Q2 2025.
  • Selectis Health's EBITDA's 5-year high stood at $1.8 million during Q2 2022, with a 5-year trough of -$2.6 million in Q4 2023.
  • For the 5-year period, Selectis Health's EBITDA averaged around -$311304.2, with its median value being -$97261.0 (2024).
  • Per our database at Business Quant, Selectis Health's EBITDA surged by 8564895.78% in 2022 and then tumbled by 166540.85% in 2023.
  • Over the past 5 years, Selectis Health's EBITDA (Quarter) stood at -$715292.0 in 2021, then plummeted by 38.18% to -$988381.0 in 2022, then crashed by 159.27% to -$2.6 million in 2023, then skyrocketed by 96.2% to -$97261.0 in 2024, then skyrocketed by 169.65% to $67739.0 in 2025.
  • Its EBITDA stands at $67739.0 for Q3 2025, versus -$87547.0 for Q2 2025 and -$58726.0 for Q1 2025.